Evidence map›Paper›PMID 41466394›Full record

Trial reportBMC musculoskeletal disorders2025

Intra-articular injection of umbilical cord-derived mesenchymal stem cells is safe and effective for moderate to severe knee osteoarthritis with synovitis: a double‑blinded and randomized controlled trial.

Wei Tong, Yangyang Shi, Dongcheng Wu, Jie Jia, E Xiang, Dongdong Xu, Wei Rao, Qin Hu, Qiwen Liao, Cuihong Xiao and 3 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in BMC musculoskeletal disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Body mass index, weight bearing, and delayed union after femoral shaft fracture nailing: a retrospective cohort study.European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Wei Tong *Department of Orthopaedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Yangyang Shi *Department of Orthopedics & Spine Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Dongcheng WuDepartment of Biochemistry and Molecular Biology, Wuhan University School of Basic Medical Sciences, Wuhan, China.
Jie JiaDepartment of Orthopaedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
E XiangWuhan Hamilton Biotechnology-Co., Ltd, Wuhan, China.
Dongdong XuDepartment of Orthopaedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Wei RaoWuhan Hamilton Biotechnology-Co., Ltd, Wuhan, China.
Qin HuWuhan Hamilton Biotechnology-Co., Ltd, Wuhan, China.
Qiwen LiaoWuhan Hamilton Biotechnology-Co., Ltd, Wuhan, China.
Cuihong XiaoWuhan Hamilton Biotechnology-Co., Ltd, Wuhan, China.
Shuo ZhengWuhan Hamilton Biotechnology-Co., Ltd, Wuhan, China.
Weihua XuDepartment of Orthopaedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Hongtao TianDepartment of Orthopaedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. tianhongtao@vip.163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo evaluate the safety and clinical efficacy of intra-articular injection of human umbilical cord–derived mesenchymal stem cells (UC-MSCs) for knee osteoarthritis (KOA).

methodsThis was a randomized, double-blind, placebo-control trial consisting of 3 arms including placebo, hyaluronic acid (HA), and UC-MSCs. 69 individuals were screened, with 55 participants subsequently randomized. The primary endpoint was the safety after injection. The secondary endpoints were improvements in visual analog scale (VAS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Knee Society Clinical Rating System (KSS), EuroQol five-dimensional questionnaire (EQ-5D), and magnetic resonance imaging (MRI) examinations at 6-month after injection.

resultsAdverse events (AEs) did not demonstrate significant differences among the groups. No serious treatment-related AEs were observed. Compared with placebo and HA, injection of UC-MSCs resulted in a greater improvement in VAS and EQ-5D; however, the differences were not statistically significant. Patients in the UC-MSCs group exhibited significant improvement in synovitis at the 6-month follow-up as compared with the placebo and HA groups (P = 0.003). At 6 months, UC-MSCs injection showed significantly better improvements in VAS (P = 0.011), WOMAC (P = 0.014), and EQ-5D scores (P = 0.049) in patients with KOA incorporating synovitis, particularly those experiencing moderate to severe pain. MRI indicated no significant difference in change of joint structures among the groups, except for the synovium.

conclusionsTreatment with UC-MSCs was shown to be a viable therapeutic option for KOA combined with synovitis, showing clinical improvement at the end of follow-up, especially in those with moderate to severe pain. Further phase III clinical trials would be required to confirm the efficacy.

trial registrationThe trial was registered at chictr.org on October 13, 2020, with the registration number ChiCTR2000039017.

Indexed as

Mesenchymal Stem Cell TransplantationOsteoarthritis, KneeSynovitisUmbilical CordAgedDouble-Blind MethodFemaleHumansHyaluronic AcidInjections, Intra-ArticularMagnetic Resonance ImagingMaleMiddle AgedPain MeasurementSeverity of Illness IndexTreatment OutcomeHyaluronic AcidCell therapyIntra-articular injectionKnee osteoarthritisMesenchymal stem cell

Identifiers

PMID41466394
PMCPMC12859901

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.